Abbott Laboratories $ABT Shares Sold by Andra AP fonden

Key Points

• Andra AP fonden cut its Abbott Laboratories stake by 77.1% in the second quarter, selling 159,400 shares and retaining 47,308 shares valued at approximately $4.3 million.
• Institutional investors own 75.18% of Abbott, while analysts maintain a “Moderate Buy” consensus with an average price target of $119.50.
• Abbott recently exceeded quarterly earnings and revenue estimates, reported 13% year-over-year revenue growth, and declared a quarterly dividend of $0.63, equivalent to a 2.4% annual yield.

Andra AP fonden reduced its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 77.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 47,308 shares of the healthcare product maker's stock after selling 159,400 shares during the period. Andra AP fonden's holdings in Abbott Laboratories were worth $4,293,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ABT. BlackRock Inc. grew its stake in Abbott Laboratories by 4.6% during the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock worth $13,843,610,000 after buying an additional 6,769,518 shares during the last quarter. State Street Corp grew its position in Abbott Laboratories by 2.1% during the 4th quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker's stock worth $10,004,880,000 after purchasing an additional 1,627,791 shares during the last quarter. Capital International Investors increased its stake in Abbott Laboratories by 2.6% in the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker's stock valued at $7,922,519,000 after purchasing an additional 1,614,706 shares during the period. J. Stern & Co. LLP increased its stake in Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker's stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares during the period. Finally, Capital Research Global Investors raised its holdings in shares of Abbott Laboratories by 1.0% in the fourth quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker's stock valued at $4,907,523,000 after buying an additional 400,400 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company's stock.

Wall Street Analyst Weigh In

ABT has been the topic of a number of research reports. UBS Group lowered their price target on Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a report on Tuesday, July 28th. Wells Fargo & Company increased their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the stock an "overweight" rating in a research report on Friday, July 17th. BTIG Research lifted their target price on Abbott Laboratories from $131.00 to $134.00 and gave the company a "buy" rating in a research note on Friday, July 17th. Bank of America dropped their target price on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Finally, The Goldman Sachs Group decreased their price target on Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating for the company in a report on Wednesday, May 27th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, Abbott Laboratories has a consensus rating of "Moderate Buy" and a consensus price target of $119.50.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott and Berry Street announced an exclusive partnership combining Abbott’s Lingo over-the-counter continuous glucose monitor with Berry Street’s insurance-covered registered-dietitian and nutrition-coaching platform. The initiative could improve Lingo adoption, expand Abbott’s consumer health ecosystem and strengthen its position in metabolic-health services. Abbott and Berry Street partnership article
• Positive Sentiment: Abbott’s Volt Pulsed Field Ablation System reportedly saw its first clinical use in Canada and at an Illinois heart center for treating atrial fibrillation. Additional real-world use could support the medical-device pipeline and future cardiovascular revenue growth. Abbott digital health and formula settlement article
• Positive Sentiment: Investor commentary continues to describe Abbott as a high-quality, diversified healthcare business with attractive long-term prospects. Its exposure to diagnostics, medical devices, nutrition and digital health provides multiple growth avenues, and the therapeutic drug-monitoring market is projected to expand substantially through 2032. What makes Abbott attractive article
• Neutral Sentiment: ABT is drawing increased attention from investors and analysts. Recent results exceeded consensus estimates, with revenue growth supported by the company’s diversified portfolio, but commentary generally characterizes the shares as a strong business available at a fair—not deeply discounted—price. Abbott trending stock article
• Negative Sentiment: Abbott agreed to pay approximately $385 million to settle infant-formula litigation. Although the settlement removes some legal uncertainty, the cash cost and reputational overhang are negative for near-term sentiment. Valuation comparisons with faster-growing healthcare companies, including Exact Sciences, may also reduce enthusiasm among growth-oriented investors. Abbott and Exact Sciences comparison article

Abbott Laboratories Price Performance

ABT stock opened at $103.62 on Thursday. The firm has a 50 day moving average of $107.15 and a 200-day moving average of $99.10. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $136.83. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The company has a market cap of $179.31 billion, a price-to-earnings ratio of 33.53, a PEG ratio of 1.92 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion for the quarter, compared to analysts' expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company's revenue was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $0.63 dividend. The ex-dividend date is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. Abbott Laboratories's dividend payout ratio (DPR) is currently 81.55%.

Abbott Laboratories Profile

Abbott Laboratories NYSE: ABT is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company's medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.